Document:

exh_104.htm

Exhibit 10.4

PLATFORM SPECIALTY PRODUCTS CORPORATION

AMENDED AND RESTATED

2013 INCENTIVE COMPENSATION PLAN

RESTRICTED STOCK UNIT AGREEMENT

 

FOR

 

___________________________

 

1.  Award of Restricted Stock Units.  Platform Specialty Products Corporation (the “Company”) hereby grants, as of _____________ (the “Date of Grant”), to _____________ (the “Recipient”), the right to receive upon vesting as provided for herein, ______ restricted shares of the Company’s common stock (collectively the “RSUs”).  The RSUs shall be subject to the terms, provisions and restrictions set forth in this Agreement and the Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (the “Plan”), which is incorporated herein for all purposes.  As a condition to entering into this Agreement, and to the issuance of any Shares (or any other securities of the Company pursuant thereto), the Recipient agrees to be bound by all of the terms and conditions herein and in the Plan.  Unless otherwise provided herein, terms used herein that are defined in the Plan and not defined herein shall have the meanings attributable thereto in the Plan.

 

2.  Vesting of RSUs.

 

(a)  General Vesting. Except as provided in Sections 2(c) and 3 of this Agreement, the RSUs shall vest on March 17, 2018 (the “Vesting Date”), if and only if (i) as to 50% of the RSU’s the Committee determines that the Company’s earnings per share of the Company for the year ended December 31, _______ (the “Measurement Year”) equals or exceeds $____ per share (the “EPS Target”) for the Measurement Year, and (ii) as to 50% of the RSU’s the Company’s publically traded common stock meets a VWAP of $_____ per share prior to the Vesting Date (the “Share Price Target”), where “VWAP” shall mean the volume weighted average price per share of the Company’s common stock on the New York Stock Exchange (or other exchange on which such equity securities are publicly traded) for twenty (20) trading days in any thirty (30) consecutive trading day period ending prior to the Vesting Date.   Thus vesting of the RSU will depend on both time and the Company’s achievement of the specified EPS TARGET. The Committee shall have plenary discretion in determining the components and accounting principles that are considered in calculating the applicable EPS.

 

(b)  Adjustments to Goals and Targets.

 

(i)           If, during the vesting period (i.e. the time between the effective date and the vesting date), the Company or any of its Related Entities consummates (whether by merger, recapitalization, consolidation, stock purchase, asset purchase or otherwise) either an acquisition of any other company or business or a disposition of any material portion of the Company’s assets, in each case, out of the ordinary course of business, (an “Acquired/Disposed Business”), the Committee may determine, in it sole discretion, to adjust the EPS Target to account for the relative impact of the Acquired/Disposed Business. Notwithstanding the foregoing, if the Committee does not determine to adjust the EPS Target within thirty (30) days following the consummation of such transactions, the results of operations of the Acquired/Disposed Business shall be excluded from the determination of EPS and the EPS Target shall not be adjusted. Adjustments that may be made by the Committee pursuant to this Agreement shall be made in accordance with the provisions and restrictions set forth in the Plan, and no adjustments shall be permitted if expressly prohibited in the Plan or may cause the RSUs to not satisfy the performance- based exception to Section 162(m) of the Code.

 

  

  

  

(c)  Acceleration of Vesting Upon Change in Control.   In the event that a Change in Control of the Company occurs during the Recipient's Continuous Service, except as provided in Section 3 hereof, the Shares subject to the RSUs subject to this Agreement shall become immediately vested as of the date of the Change in Control (the “Change in Control Vesting Date”), unless either (i) the Company is the surviving entity in the Change in Control and the RSUs continue to be outstanding after the Change in Control on substantially the same terms and conditions as were applicable immediately prior to the Change in Control or (ii) the successor company or its parent company assumes or substitutes for the RSUs, as determined in accordance with Section 10(c)(ii) of the Plan.

 

3.  Forfeiture of RSUs.

 

(a)  If the Recipient does not remain continuously actively employed by the Company for any reason prior to the earlier of (a) Vesting Date or (b) Change in Control Vesting Date, the RSUs granted hereunder shall be forfeited immediately upon such lapse in or termination of active service and the shares will be immediately canceled without recompense to or recourse by the Recipient.

 

The Committee shall have the power and authority to enforce on behalf of the Company any rights of the Company under this Agreement in the event of the Recipient’s forfeiture of RSUs pursuant to this Section 3.

 

4.        Settlement of the RSUs. The Company shall deliver to the Recipient the number of Shares corresponding to the Vested RSUs as soon as practicable on or after the Vesting Date or Change in Control Vesting Date, whichever applicable, but in no event later than the 15th day of the third month following the last day of the calendar year in which the Vesting Date or Change in Control Vesting Date, whichever applicable, occurs.

 

5.  Rights with Respect to RSUs.

 

(a)           No Rights as Shareholder Until Delivery.  Except as otherwise provided in this Section 5, the Recipient shall not have any rights, benefits or entitlements with respect to the Shares corresponding to the RSUs unless and until those Shares are delivered to the Recipient (and thus shall have no voting rights, or rights to receive any dividend declared, before those Shares are so delivered).  On or after delivery, the Recipient shall have, with respect to the Shares delivered, all of the rights of a holder of Shares granted pursuant to the articles of incorporation and other governing instruments of the Company, or as otherwise available at law.

 

  

2

  

(b)           Adjustments ⁠to Shares.  If at any time while this Agreement is in effect and before any Shares have been delivered with respect to any RSUs, there shall be any increase or decrease in the number of issued and outstanding Shares of the Company through the declaration of a stock dividend or through any recapitalization resulting in a stock split-up, combination or exchange of such Shares, then and in that event, the Committee (or Board as applicable) may make any adjustments it deems fair and appropriate, in view of such change, in the number of Shares subject to the RSUs then subject to this Agreement.  If any such adjustment shall result in a fractional Share, such fraction shall be disregarded.

 

(c)           Restriction on Certain Transactions. Notwithstanding any term or provision of this Agreement to the contrary, the existence of this Agreement, or of any outstanding RSUs awarded hereunder, shall not affect in any manner the right, power or authority of the Company or any Related Entity to make, authorize or consummate: (i) any or all adjustments, recapitalizations, reorganizations or other changes in the Company's or any Related Entity’s capital structure or its business; (ii) any merger, consolidation or similar transaction by or of the Company or any Related Entity; (iii) any offer, issue or sale by the Company or any Related Entity of any capital stock of the Company or any Related Entity, including any equity or debt securities, or preferred or preference stock that would rank prior to or on parity with the Shares represented by the RSUs and/or that would include, have or possess other rights, benefits and/or preferences superior to those that such Shares includes, has or possesses, or any warrants, options or rights with respect to any of the foregoing; (iv) the dissolution or liquidation of the Company or any Related Entity; (v) any sale, transfer or assignment of all or any part of the stock, assets or business of the Company or any Related Entity; or (vi) any other corporate transaction, act or proceeding (whether of a similar character or otherwise).

 

6.  Transferability.  The RSUs are not transferable unless and until the Shares have been delivered to the Recipient in settlement of the RSUs in accordance with this Agreement, otherwise than by will or under the applicable laws of descent and distribution. The terms of this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Recipient.  Except as otherwise permitted pursuant to the first sentence of this Section, any attempt to effect a Transfer of any RSUs prior to the date on which the Shares have been delivered to the Recipient in settlement of the RSUs shall be void ab initio.  For purposes of this Agreement, “Transfer” shall mean any sale, transfer, encumbrance, gift, donation, assignment, pledge, hypothecation, or other disposition, whether similar or dissimilar to those previously enumerated, whether voluntary or involuntary, and including, but not limited to, any disposition by operation of law, by court order, by judicial process, or by foreclosure, levy or attachment.

 

7.  Tax Matters.

 

(a)           Withholding.  As a condition to the Company’s obligations with respect to the RSUs (including, without limitation, any obligation to deliver any Shares) hereunder, the Recipient shall make arrangements satisfactory to the Company to pay to the Company any federal, state or local taxes of any kind required to be withheld with respect to the delivery of Shares corresponding to such RSUs.  If the Recipient shall fail to make the tax payments as are required, the Company shall, to the extent permitted by law, have the right to deduct from any payment of any kind (including the withholding of any Shares that otherwise would be delivered to Recipient under this Agreement) otherwise due to the Recipient any federal, state or local taxes of any kind required by law to be withheld with respect to such Shares.

 

  

3

  

 

(b)           Satisfaction of Withholding Requirements.  The Recipient may satisfy the withholding requirements with respect to the RSUs pursuant to any one or combination of the following methods:

 

(i)           payment in cash; or

 

(ii)          if and to the extent permitted by the Committee, payment by surrendering unrestricted previously held Shares which have a value equal to the required withholding amount or the withholding of Shares that otherwise would be deliverable to the Recipient pursuant to this Agreement.  The Recipient may surrender Shares either by attestation or by delivery of a certificate or certificates for Shares duly endorsed for transfer to the Company, and if required with medallion level signature guarantee by a member firm of a national stock exchange, by a national or state bank (or guaranteed or notarized in such other manner as the Committee may require).

 

(c)           Recipient’s Responsibilities for Tax Consequences.  The tax consequences to the Recipient (including without limitation federal, state, local and foreign income tax consequences) with respect to the RSUs (including without limitation the grant, vesting and/or delivery thereof) are the sole responsibility of the Recipient.  The Recipient shall consult with his or her own personal accountant(s) and/or tax advisor(s) regarding these matters and the Recipient’s filing, withholding and payment (or tax liability) obligations.

 

8.  Amendment, Modification & Assignment. This Agreement may only be modified or amended in a writing signed by the parties hereto.  No promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, with respect to the subject matter hereof, have been made by either party which are not set forth expressly in this Agreement.  Unless otherwise consented to in writing by the Company, in its sole discretion, this Agreement (and Recipient’s rights hereunder) may not be assigned, and the obligations of Recipient hereunder may not be delegated, in whole or in part.  The rights and obligations created hereunder shall be binding on the Recipient and his heirs and legal representatives and on the successors and assigns of the Company.

 

9.  Complete Agreement.  This Agreement (together with those agreements and documents expressly referred to herein, for the purposes referred to herein) embody the complete and entire agreement and understanding between the parties with respect to the subject matter hereof, and supersede any and all prior promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, which may relate to the subject matter hereof in any way.

 

  

4

  

 

10.  Miscellaneous.

 

(a)  No Right to (Continued) Employment or Service.  This Agreement and the grant of RSUs hereunder shall not confer, or be construed to confer, upon the Recipient any right to employment or service, or continued employment or service, with the Company or any Related Entity.

 

(b)  No Limit on Other Compensation Arrangements.  Nothing contained in this Agreement shall preclude the Company or any Related Entity from adopting or continuing in effect other or additional compensation plans, agreements or arrangements, and any such plans, agreements and arrangements may be either generally applicable or applicable only in specific cases or to specific persons.

 

(c)  Severability.  If any term or provision of this Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended without materially altering the purpose or intent of this Agreement and the grant of RSUs hereunder, such provision shall be stricken as to such jurisdiction and the remainder of this Agreement and the award hereunder shall remain in full force and effect).

 

(d)  No Trust or Fund Created.  Neither this Agreement nor the grant of RSUs hereunder shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Related Entity and the Recipient or any other person.  To the extent that the Recipient or any other person acquires a right to receive payments from the Company or any Related Entity pursuant to this Agreement, such right shall be no greater than the right of any unsecured general creditor of the Company.

 

(e)  Law Governing.  This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware (without reference to the conflict of laws rules or principles thereof).

 

(f)  Interpretation.  The Recipient accepts this award of RSUs subject to all of the terms, provisions and restrictions of this Agreement and the Plan.  The undersigned Recipient hereby accepts as binding, conclusive and final all decisions or interpretations of the Board or the Committee upon any questions arising under this Agreement or the Plan.

 

(g)  Headings.  Section, paragraph and other headings and captions are provided solely as a convenience to facilitate reference.  Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning or interpretation of this Agreement or any term or provision hereof.

 

(h)  Notices.  Any notice under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or when deposited in the United States mail, registered, postage prepaid, and addressed, in the case of the Company, to the Company’s Secretary at 245 Freight Street, Waterbury, Connecticut 06702, or if the Company should move its principal office, to such principal office, and, in the case of the Recipient, to the Recipient’s last permanent address as shown on the Company’s records, subject to the right of either party to designate some other address at any time hereafter in a notice satisfying the requirements of this Section.

 

  

5

  

 

(i)  Compliance with Section 409A

 

(i)  General. It is the intention of both the Company and the Recipient that the benefits and rights to which the Recipient could be entitled pursuant to this Agreement either comply with or fall within an exception to Section 409A of the Code and the Treasury Regulations and other guidance promulgated or issued thereunder (“Section 409A”), to the extent that the requirements of Section 409A are applicable thereto, and the provisions of this Agreement shall be construed in a manner consistent with that intention.

 

(ii)  No Representations as to Section 409A Compliance.  Notwithstanding the foregoing, the Company does not make any representation to the Recipient that the shares of RSUs awarded pursuant to this Agreement are exempt from, or satisfy, the requirements of Section 409A, and the Company shall have no liability or other obligation to indemnify or hold harmless the Recipient or any Beneficiary for any tax, additional tax, interest or penalties that the Recipient or any Beneficiary may incur in the event that any provision of this Agreement, or any amendment or modification thereof or any other action taken with respect thereto is deemed to violate any of the requirements of Section 409A.

 

(iii)  No Acceleration of Payments.  Neither the Company nor the Recipient, individually or in combination, may accelerate any payment or benefit that is subject to Section 409A, except in compliance with Section 409A and the provisions of this Agreement, and no amount that is subject to Section 409A shall be paid prior to the earliest date on which it may be paid without violating Section 409A.

 

(j)  Non-Waiver of Breach.  The waiver by any party hereto of the other party's prompt and complete performance, or breach or violation, of any term or provision of this Agreement shall be effected solely in a writing signed by such party, and shall not operate nor be construed as a waiver of any subsequent breach or violation, and the waiver by any party hereto to exercise any right or remedy which he or it may possess shall not operate nor be construed as the waiver of such right or remedy by such party, or as a bar to the exercise of such right or remedy by such party, upon the occurrence of any subsequent breach or violation.

 

(k)  Counterparts.  This Agreement may be executed in two or more separate counterparts, each of which shall be an original, and all of which together shall constitute one and the same agreement.

 

(l)  Clawback of Benefits.  The Company may (i) cause the cancellation of the RSUs, (ii) require reimbursement of any benefit conferred under the RSUs to the Recipient or Beneficiary, and (iii) effect any other right of recoupment of equity or other compensation provided under the Plan or otherwise in accordance with any Company policies that currently exist or that may from time to time be adopted or modified in the future by the Company and/or applicable law (each, a “Clawback Policy”).  In addition, the Recipient may be required to repay to the Company certain previously paid compensation, whether provided under the Plan or an Award Agreement or otherwise, in accordance with any Clawback Policy.  By accepting this Award, the Recipient agrees to be bound by any existing or future Clawback Policy adopted by the Company, or any amendments that may from time to time be made to the Clawback Policy in the future by the Company in its discretion (including without limitation any Clawback Policy adopted or amended to comply with applicable laws or stock exchange requirements) and further agrees that all of the Recipient’s Award Agreements (and/or awards issued under the Prior Plan) may be unilaterally amended by the Company, without the Recipient’s consent, to the extent that the Company in its discretion determines to be necessary or appropriate to comply with any Clawback Policy.

 

  

6

  

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the _____day of __________.

 

	 	COMPANY:
	 	 	 	 
	 	
PLATFORM SPECIALTY PRODUCTS 

CORPORATION, a Delaware corporation

	 	 	 	 
	 	By: 	 	 
	 	
Name:

	 
	 	
Title:

	 

 

 

The Recipient acknowledges receipt of a copy of the Plan and represents that he or she has reviewed the provisions of the Plan and this Agreement in their entirety, is familiar with and understands their terms and provisions, and hereby accepts this RSU award subject to all of the terms and provisions of the Plan and the Agreement.  The Recipient further represents that he or she has had an opportunity to obtain the advice of counsel prior to executing this Agreement.

 

	Dated: 	 	 	RECIPIENT:	 
	 	 	 	 	 

 

 

 

 

7Exhibit 4.4

 

Dated 23 February 2015

 

	
(1)
    	
ADAPTIMMUNE THERAPEUTICS   LIMITED
    
	
 
    	
 
    
	
(2)
    	
EACH OF THE SELLERS
    

 

 

SHARE FOR SHARE EXCHANGE AGREEMENT

relating to Adaptimmune Limited

 

 

Strictly private and confidential

 

MAYER ·  BROWN

 

LONDON

 

 

CONTENTS

 

	
Clause
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
1.
    	
Definitions   and interpretation
    	
 
    	
1
    
	
2.
    	
Agreement   to sell and purchase
    	
 
    	
3
    
	
3.
    	
Consideration
    	
 
    	
4
    
	
4.
    	
Completion
    	
 
    	
5
    
	
5.
    	
Notices
    	
 
    	
6
    
	
6.
    	
Entire   agreement
    	
 
    	
6
    
	
7.
    	
General
    	
 
    	
7
    
	
8.
    	
Counterparts
    	
 
    	
7
    
	
9.
    	
Governing   law and jurisdiction
    	
 
    	
7
    
	
 
    	
 
    	
 
    	
 
    
	
Schedules
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
1.
    	
Newco   Warranties
    	
 
    	
 
    
	
2.
    	
Seller   Warranties
    	
 
    	
 
    
	
3.
    	
Sellers’   details
    	
 
    	
 
    

 

 

THIS AGREEMENT is dated 23 February 2015 and made between:

 

(1)                                 ADAPTIMMUNE THERAPEUTICS LIMITED (registered number 09338148) whose registered office is at 91 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY (“Newco”); and

 

(2)                                 THOSE OF THE PERSONS whose names and addresses are listed in column 1 of Schedule 3 (Sellers’ details) who at the date of this Agreement are the registered owners of shares in the capital of Adaptimmune who have executed this Agreement below (collectively the “Sellers” and each a “Seller”).

 

BACKGROUND:

 

(A)                               Adaptimmune Limited (“Adaptimmune”) is a private company limited by shares incorporated in England and Wales on 19 December 2007 with registered number 06456741, and has a share capital comprising Ordinary Shares and Series A Preferred Shares.

 

(B)                               The Sellers are the registered owners of the number of shares each in the capital of Adaptimmune set out against their respective names in columns 2 and 4 of Schedule 3 (Sellers’ details) (together the “Adaptimmune Shares”) which comprise the entire issued share capital of Adaptimmune.

 

(C)                               Newco is a private company limited by shares incorporated in England and Wales on 3 December 2014 with registered number 09338148, and has a share capital comprising ordinary shares of £0.001 each (the “Newco Ordinary Shares”) and series A preferred shares of £0.001 each (the “Newco Preferred Shares”), of which one Newco Ordinary Share is in issue and is held by the Newco Subscriber fully paid.

 

(D)                               Newco has made a general offer to acquire the whole of the issued share capital of Adaptimmune and the Sellers have each agreed to transfer to Newco their respective entire holdings of Adaptimmune Shares in consideration for the issue to them by Newco of Newco Ordinary Shares and/or Newco Preferred Shares (as the case may be) in respect of and in proportion to their Adaptimmune Shares.

 

(E)                                The Newco Subscriber, who already holds one Newco Ordinary Share, has waived his pro-rata entitlement to consideration to the extent of one Newco Ordinary Share.

 

(F)                                 The transactions contemplated by this Agreement are intended to qualify as a tax-free reorganisation under section 368 of the US Internal Revenue Code of 1986, as amended.

 

IT IS AGREED that:

 

1.                                      DEFINITIONS AND INTERPRETATION

 

1.1                               Defined Terms

 

In this Agreement:

 

“Agreed Terms” means, in relation to any document, that document in the terms agreed between Newco and the relevant party(ies), and signed or initialled for

 

1

 

identification purposes only by or on behalf of Newco and the relevant other party(ies) prior to the execution of this Agreement;

 

“Business Day” shall mean a day except a Saturday or Sunday, on which banks in the City of London are open for business generally;

 

“Completion” shall mean completion of the sale and purchase of the Adaptimmune Shares in accordance with Clause 4 (Completion);

 

“Consideration Shares” means, in aggregate, the Newco Ordinary Shares and/or Newco Preferred Shares (as the case may be) to be allotted and issued to the Sellers in accordance with Clause 3 (Consideration);

 

“Fidelity Letter” means the agreement between Newco, Adaptimmune and Beacon Bioventures Fund III Limited Partnership in the Agreed Terms;

 

“Investors’ Rights Agreement” means the agreement of that name in the Agreed Terms to be entered into between Newco, Adaptimmune and certain of the Sellers;

 

“NEA Letter” means the agreement between Newco, Adaptimmune and New Enterprise Associates 14, L.P. in the Agreed Terms;

 

“Newco Subscriber” means James Noble, who holds one Newco Ordinary Share paid up at par as at the date of this Agreement;

 

“Newco Warranties” means the statements set out in Schedule 1 (Newco Warranties);

 

“Ordinary Shares” means the ordinary shares of £0.001 each in the capital of Adaptimmune;

 

“Seller Warranties” means the statements set out in Schedule 2 (Seller Warranties);

 

“Series A Preferred Shares” means the series A preferred shares of £0.001 each in the capital of Adaptimmune;

 

“Shareholders Agreement” means the agreement of that name in the Agreed Terms to be entered into between Newco, Adaptimmune and the Sellers;

 

“Wellington Letter” means the agreement between Newco, Adaptimmune and certain of the Sellers in the Agreed Terms;

 

“Written Resolution” means the written resolution of the shareholders of Adaptimmune amending the articles of association of Adaptimmune by the insertion of a new article 10.6; and

 

“2014 Shareholders’ Agreement” means the amended and restated shareholders’ agreement relating to Adaptimmune dated 23 September 2014, which agreement will be terminated pursuant to the Shareholders Agreement.

 

2

 

1.2                               Contents and headings

 

In this Agreement, the contents page and headings are included for convenience only and shall not affect the interpretation or construction of this Agreement.

 

1.3                               References in the Agreement

 

In this Agreement, unless the context requires otherwise, any reference to:

 

(a)                                 a “party” or “the parties” is to a party or the parties (as the case may be) to this Agreement and includes the respective permitted assignees of a party;

 

(b)                                 the Background is to the statements about the background to this Agreement made above and Clause or a Schedule is to a clause of or a schedule to this Agreement;

 

(c)                                  this Agreement includes the Schedules which form part of this Agreement for all purposes;

 

(d)                                 a statute or statutory provision includes any consolidation, re-enactment, modification or replacement of the same, any statute or statutory provision of which it is a consolidation, re-enactment, modification or replacement and any subordinate legislation in force under the same from time to time except to the extent that any consolidation, re-enactment, modification or replacement enacted after the date of this Agreement would extend or increase the liability of any party to the other under this Agreement;

 

(e)                                  the masculine, feminine or neuter gender respectively includes the other genders, references to the singular include the plural (and vice versa);

 

(f)                                   a person includes any individual, firm, corporation, unincorporated associations, government, state, association, partnership or joint venture (whether or not having separate legal personality);

 

(g)                                  writing shall include any modes of reproducing words in a legible and non transitory form; and

 

(h)                                 sterling or £ or pounds or pence is to the lawful currency of the United Kingdom.

 

2.                                      AGREEMENT TO SELL AND PURCHASE

 

2.1                               Sale and purchase

 

Subject to the terms of this Agreement, Newco shall purchase and each of the Sellers shall sell the entire legal and beneficial ownership in the number and class of Adaptimmune Shares set opposite their respective names in columns 2 and 4 of Schedule 3 (Sellers’ details) free from all claims, liens, charges and encumbrances and together with all rights attached or accruing to such Adaptimmune Shares, including the right to all dividends and other distributions hereafter declared made or paid.

 

3

 

2.2                               Sellers’ covenants

 

Each Seller severally covenants in relation to himself only that:

 

(a)                                 he is the registered holder of the number and class of Adaptimmune Shares set out opposite his name in columns 2 and 4 of Schedule 3 (Sellers’ details);

 

(b)                                 he has the full power and the right to transfer the legal and beneficial title in the Adaptimmune Shares set out opposite his name in columns 2 and 4 of Schedule 3 (Sellers’ details);

 

(c)                                  the Adaptimmune Shares set out opposite his name in columns 2 and 4 of Schedule 3 (Sellers’ details) shall, on Completion, be free from all encumbrances and from all other rights exercisable by third parties;

 

(d)                                 he will at Completion execute such documents as are reasonably necessary to transfer the legal and beneficial title in the Adaptimmune Shares set out opposite his name in columns 2 and 4 of Schedule 3 (Sellers’ details) to Newco and secure to Newco all the rights attaching to such Adaptimmune Shares;

 

(e)                                  the number and class of shares set out opposite his name in columns 2 and 4 of Schedule 3 (Sellers’ details) constitute all of the Adaptimmune Shares registered in his name; and

 

(f)                                   the allotment and issue of Consideration Shares pursuant to this Agreement is in full satisfaction of any right which he may have (including any such right arising under the articles of association of Adaptimmune) in respect of the transfer by him of his Adaptimmune Shares, and he hereby waives any such right to the extent not fully satisfied.

 

2.3                               Newco’s warranties

 

Newco warrants (at the date of this Agreement) to each of the Sellers in the terms of the Newco Warranties. Newco acknowledges that each of the Sellers has entered into this Agreement in reliance on the Newco Warranties.

 

2.4                               Sellers’ warranties

 

Each of the Sellers warrants to Newco, severally and not jointly, in the terms of the Seller Warranties. Each of the Sellers acknowledges that Newco has entered into this Agreement in reliance on the Seller Warranties. All other obligations of the Sellers in this Agreement are given severally and not jointly.

 

2.5                               Waiver of pre-emption rights

 

Each of the Sellers irrevocably waives and shall procure the waiver of all rights of pre-emption over or other rights to restrict the transfer of the Adaptimmune Shares either by the articles of association of Adaptimmune or by the 2014 Shareholders’ Agreement (and particularly clause 7 thereof) or in any other way.

 

4

 

2.6                               Amendment of Adaptimmune articles

 

Each of the Sellers:

 

(a)                                 confirms that its execution of the Written Resolution constituted its prior consent for the purposes of the 2014 Shareholders’ Agreement to the amendment of the articles of association of Adaptimmune as contemplated by the Written Resolution; and

 

(b)                                 consents to the reorganisation to be effected pursuant to this Agreement for the purposes of the new article 10.6 inserted into the articles of association of Adaptimmune pursuant to the Written Resolution.

 

3.                                      CONSIDERATION

 

The consideration for the Adaptimmune Shares shall be wholly satisfied by the allotment and issue by Newco to each Seller of the number and class of shares in the capital of Newco as set out against his name in columns 3 and 5 of Schedule 3 (Sellers’ details) (being one hundred Newco Ordinary Shares for each Ordinary Share transferred to Newco and one hundred Newco Preferred Shares for each Series A Preferred Share transferred to Newco, (provided that in the case of the Newco Subscriber he shall be allotted and issued one Newco Ordinary Share less than the number set out against his name in column 2 of Schedule 3 (Sellers’ details) to reflect the one Newco Ordinary Share already held by him)), credited as fully paid.

 

4.                                      COMPLETION

 

4.1                               Completion

 

Completion shall occur as soon as reasonably practicable after execution of this Agreement by all of the Sellers when:

 

(a)                                 each Seller shall deliver (or shall procure to be delivered) to Newco:

 

(i)                                     a duly completed and executed instrument of transfer in favour of Newco in respect of the Adaptimmune Shares set out opposite his name in columns 2 and 4 of Schedule 3 (Sellers’ details), together with the share certificate(s) for such Adaptimmune Shares (or an indemnity in the form prescribed by Newco in the case of any lost certificate) and any power of attorney or other authority under which those transfers have been executed; and

 

(ii)                                  the Shareholders’ Agreement duly executed by that Seller;

 

(b)                                 each Seller that is a party to the Investors’ Rights Agreement shall deliver (or shall procure to be delivered) to Newco the Investors’ Rights Agreement duly executed by that Seller;

 

(c)                                  the Sellers, having procured prior to the entry into of this Agreement the passing of the Written Resolution, shall each deliver to Newco a copy of the Written Resolution duly executed by that Seller;

 

5

 

(d)                                 the Sellers shall execute and do (or procure to be executed or done) all such other documents, acts or things as are reasonably necessary in order to perfect the title of Newco to, and its registration as holder of, the Adaptimmune Shares; and

 

(e)                                  Newco shall:

 

(i)                                     allot and issue, credited as fully paid, the Consideration Shares pursuant to Clause 3 in the numbers set against the Sellers’ respective names in columns 3 and 5 of Schedule 3 (Sellers’ details);

 

(ii)                                  update the register of members to record the allotment and issue of shares pursuant to the terms of this Agreement;

 

(iii)                               deliver to each Seller relevant share certificates in respect of the Consideration Shares or retain any such share certificate to be held to the relevant Seller’s order if so requested;

 

(iv)                              deliver:

 

(A)                               the Shareholders’ Agreement duly executed by Newco and Adaptimmune to the Sellers;

 

(B)                               the Investors’ Rights Agreement duly executed by Newco and Adaptimmune to each Seller that is a party to the Investors’ Rights Agreement;

 

(C)                               the NEA Letter, the Wellington Letter and the Fidelity Letter each duly executed by Newco to the relevant recipient in each case.

 

4.2                               Parties not obliged to complete

 

None of the parties shall be obliged to complete this Agreement unless the other parties comply with the requirement of Clause 4.1.

 

4.3                               Obligation on Newco

 

If Newco does not otherwise re-register as a public company, Newco shall re-register as a public company in accordance with section 755(3) Companies Act 2006 no later than six months from 12 February 2015 if and to the extent that, in connection with the transactions contemplated by this Agreement, Newco has taken any action that would contravene section 755(1) Companies Act 2006 if Newco did not so re-register.

 

4.4                               US Internal Revenue Service filing

 

No later than thirty (30) days after Completion, Newco shall cause Adaptimmune to file with the US Internal Revenue Service a Form 8832 to elect to classify Adaptimmune as an entity disregarded as separate from its owner, Newco, for US federal income tax purposes, with such election to take effect on the second (2nd) day following Completion.

 

6

 

5.                                      NOTICES

 

All notices and communications relating to this Agreement shall be:

 

(a)                                 in English and in writing;

 

(b)                                 delivered by hand or sent by post or facsimile, to the addresses set out for each respective party in this Agreement shown at the start of this Agreement or, in the case of the Sellers, in Schedule 3 (Sellers’ details) (or such other address as may be notified from time to time in accordance with this clause by the relevant party to the other parties);

 

(c)                                  shall take effect:

 

(i)                                     if delivered by hand, upon delivery;

 

(ii)                                  if posted, at the earlier of delivery and, if posted in the United Kingdom by first class registered post, 10.00 a.m. on the second Business Day after posting or if posted outside the United Kingdom by first class registered post, 10.00 a.m. on the fifth Business Day after posting;

 

(iii)                               if sent by facsimile, when a complete and legible copy of the communication, whether that sent by facsimile or a hard copy sent by post or delivered by hand, has been received at the appropriate address,

 

provided that if any communication would otherwise become effective on a non Business Day or after 5.00 p.m. on a Business Day, it shall instead become effective at 10.00 a.m. on the next Business Day and if it would otherwise become effective at before 9.00 a.m. on a Business Day, it shall instead become effective at 10.00 a.m. on that Business Day.

 

6.                                      ENTIRE AGREEMENT

 

6.1                               Entire contract

 

It is hereby acknowledged that this Agreement constitutes the entire contract between the parties and supersedes all prior agreements, understandings or arrangements (both oral and written) relating to the subject matter of this Agreement.

 

6.2                               Amendment or variation

 

No amendment, change or addition to this Agreement shall be effective or binding on any party unless reduced to writing and executed by all the parties hereto.

 

6.3                               No rights of third parties

 

No person other than a party hereto shall have any rights under this Agreement. The Contracts (Rights of Third Parties) Act 1999 shall not apply to this Agreement.

 

7

 

7.                                      GENERAL

 

7.1                               Further assurance and assistance

 

The parties shall, and shall use all reasonable efforts to procure that any other person shall, do and execute and perform all such further deeds, documents, assurances, acts and things as may reasonably be required to give effect to this Agreement.

 

7.2                               Agreement binding on successors and permitted assignees

 

No party shall be entitled to assign or in any other way dispose of any or all of its rights or obligations under this Agreement. This Agreement shall be binding on each party’s successors in title or personal representatives or permitted assigns.

 

7.3                               Continuing effect

 

The provisions of this Agreement, to the extent not performed at Completion, shall remain in full force and effect, despite Completion. The Warranties shall not in any respect be extinguished or affected by Completion.

 

7.4                               Costs

 

Each party shall be responsible for the costs and expenses incurred by it in connection with the preparation and completion of this Agreement and with the sale and purchase under this Agreement.

 

7.5                               Waivers

 

No relaxation, forbearance, indulgence or delay of any party in exercising any right shall be construed as a waiver of the right and shall not affect the ability of that party subsequently to exercise that right or to pursue any remedy.

 

8.                                      COUNTERPARTS

 

This Agreement may be executed in any number of counterparts and by the parties on separate counterparts but all the counterparts shall together constitute but one and the same instrument.

 

9.                                      GOVERNING LAW AND JURISDICTION

 

9.1                               Governing law

 

This Agreement shall be governed by and construed in accordance with English law.

 

9.2                               Jurisdiction

 

The parties irrevocably agree that the courts of England are to have exclusive jurisdiction to settle any disputes which may arise out of or in connection with this Agreement.

 

8

 

EXECUTION:

 

The parties have shown their acceptance of the terms of this Agreement by signing it after the Schedules.

 

9

 

SCHEDULE 1

NEWCO WARRANTIES

 

1.                                      CAPACITY

 

1.1                               Newco has now, and will at Completion have, power under its articles of association to enter into and perform this Agreement without the necessity for any further sanction or consent by members of Newco or any class of them and all other authorisations, approvals and consents required for the entry into and performance of this Agreement by Newco have been obtained and remain in full force and effect.

 

1.2                               This Agreement has been duly authorised, executed and delivered by Newco and constitutes, or will constitute, a valid and legally binding agreement of Newco, enforceable in accordance with its terms.

 

1.3                               The Consideration Shares to be issued pursuant to this Agreement will be duly and validly authorised and issued and will be fully paid; there are no restrictions on the issue of the Consideration Shares by Newco as contemplated in this Agreement and there are no restrictions on subsequent transfers of the Consideration Shares (save as set out in the articles of association of Newco).

 

2.                                      TRADING

 

Newco is not and has never been engaged in any manner in the carrying on of any trade or business and (save as expressly provided in or contemplated by this Agreement or in respect of its incorporation):

 

(a)                                 does not have any indebtedness, mortgages, charges, debentures, guarantees or other commitments or liabilities actual or contingent;

 

(b)                                 does not have any employees;

 

(c)                                  is not party to any contract;

 

(d)                                 has not given any power of attorney or other authority to any person;

 

(e)                                  is not a party to any litigation or arbitration and there is no litigation arbitration or other legal proceedings pending or threatened against Newco;

 

(f)                                   is not the lessee of any property; and

 

(g)                                  does not have any assets.

 

3.                                      LEGAL REQUIREMENTS

 

Newco has complied in all material respects with the provisions of the Companies Act 2006 and other relevant legislation.

 

10

 

4.                                      SUBSIDIARIES

 

Newco has not and has never had any subsidiaries and (save as expressly provided in or contemplated by this Agreement) does not have the benefit of any option or agreement to acquire all or any part of the share or loan capital of any body corporate.

 

5.                                      CONSTITUTION

 

The information in paragraph C of the Background is true, complete and accurate in all respects and not (whether by omission or otherwise) misleading.

 

6.                                      SHARE AND LOAN CAPITAL

 

Save for options entitled to be granted to existing holders of options to acquire Ordinary Shares (which will replicate their existing options over Ordinary Shares), there is not outstanding any right (whether present or future and whether contingent or not) under which any person may call for the allotment, issue, sale or transfer of any share or loan capital of Newco (including option, pre emption and conversion rights), and there are no claims, liens, charges, equities or encumbrances on the shares of Newco and no dividends or other rights or benefits have been declared made or paid or agreed to be declared made or paid.

 

7.                                      STATUTORY BOOKS

 

The statutory books (including all registers and minute books) of Newco have been properly kept and contain a complete and accurate record of the matters which should be dealt with in them, and no notice or allegation that any of them is incorrect or should be rectified has been received.

 

11

 

SCHEDULE 2

SELLER WARRANTIES

 

1.                                      PURCHASE ENTIRELY FOR OWN ACCOUNT

 

The Seller hereby confirms, that the Consideration Shares to be acquired by the Seller will be acquired for investment for the Seller’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Seller has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Seller further represents that the Seller does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Consideration Shares. The Seller has not been formed for the specific purpose of acquiring the Consideration Shares.

 

2.                                      RESTRICTED SECURITIES

 

The Seller understands that the Consideration Shares have not been, and will not be, registered under the US Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Seller’s representations as expressed herein. The Seller understands that the Consideration Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Seller must hold the Consideration Shares indefinitely unless they are registered with the US Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Seller acknowledges that Newco has no obligation to register or qualify the Consideration Shares, or the Newco Ordinary Shares into which the Newco Preferred Shares may be converted, for resale except as set forth in the Investor’s Rights Agreement. The Seller further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Consideration Shares, and on requirements relating to Newco which are outside of the Seller’s control, and which Newco is under no obligation to fulfil and may not be able to satisfy.

 

3.                                      NO PUBLIC MARKET

 

The Seller understands that no public market now exists for the Consideration Shares, and that Newco has made no assurances that a public market will ever exist for the Consideration Shares.

 

4.                                      LEGENDS

 

The Seller understands that the Consideration Shares and any securities issued in respect of or exchange for the Consideration Shares, may be notated with one or all of the following legends:

 

(a)                                 “THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF

 

12

 

1933, AS AMENDED AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED.”

 

(b)                                 Any legend required by applicable U.K. securities laws or the securities laws of any state to the extent such laws are applicable to the Consideration Shares represented by the certificate, instrument, or book entry so legended.

 

5.                                      ACCREDITED INVESTOR; REGULATION S

 

The Seller is either (a) an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act, and/or (b) is a non-US person outside the United States as defined in Regulation S promulgated under the Securities Act.

 

6.                                      FOREIGN INVESTORS

 

If the Seller is not a United States person (as defined by Section 7701(a)(3) of the US Internal Revenue Code of 1986), the Seller hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to acquire for the Consideration Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the acquisition of the Consideration Shares, (ii) any foreign exchange restrictions applicable to such acquisition, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the acquisition, holding, redemption, sale, or transfer of the Consideration Shares. The Seller’s acquisition and continued beneficial ownership of the Consideration Shares will not violate any securities or other laws of the Seller’s jurisdiction in each case that are applicable to such Seller.

 

7.                                      NO GENERAL SOLICITATION

 

Neither the Seller, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer and acquisition of the Consideration Shares.

 

8.                                      RESIDENCE

 

If the Seller is an individual, then the Seller resides in the state or province identified in the address of the Seller set forth in Schedule 3 (Sellers’ details); if the Seller is a partnership, corporation, limited liability company or other entity, then the office or offices of the Seller in which its principal place of business is identified in the address or addresses of the Seller set forth in Schedule 3 (Sellers’ details).

 

13

 

SCHEDULE 3

SELLERS’ DETAILS

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
J J Noble
    	
 
    	
99,726
    	
 
    	
9,972,599
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Flat 12, Victoria   Gardens,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
15 Marston Ferry Road,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxford,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX2 7EF
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
N J Cross
    	
 
    	
290,428
    	
 
    	
29,042,800
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Lashford House,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Church Lane,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Dry Sandford,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Abingdon, Oxfordshire,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX13 6JP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
I M Laing
    	
 
    	
290,428
    	
 
    	
29,042,800
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4 Charlbury Road,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxford,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX2 6UT
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
B K Jakobsen
    	
 
    	
47,365
    	
 
    	
4,736,500
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Flat 7, Lincombe Lodge,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Fox Lane,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Boars Hill,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxford
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX1 5DN
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

14

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
B H   Jakobsen
    	
 
    	
25,125
    	
 
    	
2,512,500
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Long   Acre,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Faringdon   Road,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Frilford   Heath,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Abingdon,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxfordshire   OX13 6QJ
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
G E   S Robinson
    	
 
    	
290,428
    	
 
    	
29,042,800
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
20   Campden Hill Square,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
London   W8 7JY
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Joanne   Noble
    	
 
    	
7,143
    	
 
    	
714,300
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
38   Beech Croft Road,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxford   OX2 7AZ
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
W T   Chown
    	
 
    	
14,337
    	
 
    	
1,433,700
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4   Rawlinson Road, Oxford
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX2   6UE
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
N S   Blackwell
    	
 
    	
94,668
    	
 
    	
9,466,800
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
The   Ham, Wantage,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxfordshire
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX12   9JA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

15

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
C   Blackwell
    	
 
    	
46,222
    	
 
    	
4,622,200
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
The   Ham,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Wantage,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxfordshire
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX12   9JA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
The   Trustees of the Nigel
    	
 
    	
89,218
    	
 
    	
8,921,800
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Blackwell   A&M Trust
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
The   Ham,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Wantage,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxfordshire
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX12   9JA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
J   Pointer
    	
 
    	
46,920
    	
 
    	
4,692,000
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Heathfield   House,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Chilworth   Road,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Southampton,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
S016   7JZ
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
J   Knowles
    	
 
    	
70,676
    	
 
    	
7,067,600
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Paradiesstrasse   73,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CH4102   Binningen,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Baselland,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Switzerland
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

16

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
V E   Treves
    	
 
    	
5,576
    	
 
    	
557,600
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4   Alwyne Place,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
London
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
N1   2NL
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Quester   Academic GP
    	
 
    	
15,640
    	
 
    	
1,564,000
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Limited   as General Partner
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
of   the Second Isis College
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Fund   Limited Partnership
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Smithfield   Business
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Centre,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5 St   John’s Lane,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
London,   EC1 4BH
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
The   Chancellor, Masters
    	
 
    	
7,871
    	
 
    	
787,100
    	
 
    	
28,113
    	
 
    	
2,811,300
    	
 
    
	
and   Scholars of the
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
University   of Oxford
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
University   Offices
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Wellington   Square
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxford   OX1 2JD
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

17

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
Financial   Consultants
    	
 
    	
13,295
    	
 
    	
1,329,500
    	
 
    	
16,939
    	
 
    	
1,693,900
    	
 
    
	
(Jersey)   Limited
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
a/c   91 - Centenary House,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
La   Grande Route de St
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Pierre,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
St   Peter, Jersey
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JE3   7AY
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Nuframe   Limited
    	
 
    	
13,295
    	
 
    	
1,329,500
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Centenary   House,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
La   Grande Route de St
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Pierre,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
St   Peter,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Jersey   JE3 7AY
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
St   Catherine’s College in
    	
 
    	
4,695
    	
 
    	
469,500
    	
 
    	
16,939
    	
 
    	
1,693,900
    	
 
    
	
the   University of Oxford
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Manor   Road
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxford
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OX1   3UJ
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Peter   Lammer
    	
 
    	
52,728
    	
 
    	
5,272,800
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Manor   Cottage,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Church   Lane,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Dry   Sandford,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxfordshire   OX13 6JP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

18

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
Helen   Katrina Tayton-
    	
 
    	
18,150
    	
 
    	
1,815,000
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Martin
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Brock   House,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Sheepdrove,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Lambourn,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Hungerford,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Berks
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
RG17   7XA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Immunocore   Limited
    	
 
    	
269,767
    	
 
    	
26,976,700
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
90   Park Drive,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Milton   Park,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Abingdon,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Oxfordshire,   OX14 4RY
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
New   Enterprise Associates
    	
 
    	
 
    	
 
    	
 
    	
 
    	
592,690
    	
 
    	
59,269,000
    	
 
    
	
14,   Limited Partnership
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
c/o   New Enterprise
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Associates
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1954   Greenspring Drive,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Suite 600
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Timonium,   MD 21093
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

19

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
NEA   Ventures 2014, Limited Partnership
    	
 
    	
 
    	
 
    	
 
    	
 
    	
170
    	
 
    	
17,000
    	
 
    
	
c/o   New Enterprise Associates
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1954   Greenspring Drive,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Suite 600
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Timonium, MD 21093
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
OrbiMed   Private Investments V, LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
254,083
    	
 
    	
25,408,300
    	
 
    
	
c/o   OrbiMed Advisors, LLC
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
601 Lexington Avenue,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
54th Floor, New York,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
NY10022
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
SMALLCAP   World Fund, Inc.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
169,389
    	
 
    	
16,938,900
    	
 
    
	
c/o   Capital Research and Management Company,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Attention: Erik A,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Vayntrub,   333 South Hope
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Street, 33rd Floor, Los
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Angeles,   California 90071
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

20

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Beacon   Bioventures Fund
    	
 
    	
 
    	
 
    	
 
    	
 
    	
135,511
    	
 
    	
13,551,100
    	
 
    
	
III Limited Partnership
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
c/o Fidelity Biosciences
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
One   Main Street, 13th Floor
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Cambridge, MA 02142
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Ridgeback   Capital Management LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
118,572
    	
 
    	
11,857,200
    	
 
    
	
75 Ninth Avenue,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5th Floor
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
New York, NY 10011
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Foresite   Capital Fund II, LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
84,694
    	
 
    	
8,469,400
    	
 
    
	
101 California St.,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Suite 4100
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
San   Francisco, CA 94111
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Novo A/S
    	
 
    	
 
    	
 
    	
 
    	
 
    	
84,694
    	
 
    	
8,469,400
    	
 
    
	
Tuborg Havnevej 19
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
DK-2900 Hellerup
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Denmark
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

21

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Salthill   Investors (Bermuda) L.P.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
34,479
    	
 
    	
3,447,900
    	
 
    
	
c/o Wellington
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Management   Company, LLP,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
280 Congress Street.,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
31st Fl.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Boston MA 02210
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Salthill Partners, L.P.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50,215
    	
 
    	
5,021,500
    	
 
    
	
c/o Wellington
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Management   Company, LLP,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
280 Congress Street.,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
31st Fl.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Boston MA 02210
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Bryan White
    	
 
    	
 
    	
 
    	
 
    	
 
    	
11,240
    	
 
    	
1,124,000
    	
 
    
	
601 Union Street,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
56th Floor
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Seattle, WA 98103
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

22

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
QVT Fund V LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
29,738
    	
 
    	
2,973,800
    	
 
    
	
c/o QVT Financial LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1177   Avenue of the Americas,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
9th Floor
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
New York, NY 10036
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
QVT Fund IV LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5,021
    	
 
    	
502,100
    	
 
    
	
c/o QVT Financial LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1177   Avenue of the Americas,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
9th Floor
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
New York, NY 10036
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Quintessence Fund L.P.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
3,861
    	
 
    	
386,100
    	
 
    
	
c/o QVT Financial LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1177   Avenue of the Americas,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
9th Floor
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
New York, NY 10036
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

23

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Fourth   Avenue Capital Partners LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
34,834
    	
 
    	
3,483,400
    	
 
    
	
c/o QVT Financial LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1177   Avenue of the Americas,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
9th Floor
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
New York, NY 10036
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Rock   Springs Capital Master Fund LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
33,878
    	
 
    	
3,387,800
    	
 
    
	
650 S. Exeter Street
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Suite 1070
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Baltimore, MD 21202
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
venBio   Select Fund LLC
    	
 
    	
 
    	
 
    	
 
    	
 
    	
33,878
    	
 
    	
3,387,800
    	
 
    
	
120 West 45th Street
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Suite 2802
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
New York, NY 10036
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Merlin Nexus IV, LP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
16,939
    	
 
    	
1,693,900
    	
 
    
	
424 West 33rd Street,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Suite 330
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
New York, NY 10001
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

24

 

	
 
    	
 
    	
 
    	
 
    	
(3)
    	
 
    	
 
    	
 
    	
(5)
    	
 
    
	
 
    	
 
    	
(2)
    	
 
    	
Number of Newco
    	
 
    	
(4)
    	
 
    	
Number of Newco
    	
 
    
	
(1)
    	
 
    	
Number of Ordinary
    	
 
    	
Ordinary Shares to be
    	
 
    	
Number of Series A
    	
 
    	
Preferred Shares to be
    	
 
    
	
Seller name and address
    	
 
    	
Shares to be sold
    	
 
    	
issued
    	
 
    	
Preferred Shares to be sold
    	
 
    	
issued
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Sigal   Family Investments, LLC
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2,541
    	
 
    	
254,100
    	
 
    
	
32 Brearly Road,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Princeton, NJ 08540
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

25

 

	
EXECUTION:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
ADAPTIMMUNE THERAPEUTICS LIMITED
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Ian Michael Laing
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
Ian Michael Laing
    	
 
    
	
 
    	
 
    	
 
    
	
Title:
    	
Director
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ M. Henry
    	
 
    
	
 
    	
 
    	
 
    
	
Name: Margaret Henry
    	
 
    
	
Title: Company Secretary
    	
 
    

 

26

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 13
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for JAMES
    	
)
    	
 
    
	
NOBLE:
    	
)
    	
 
    

 

27

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated
    	
)
    	
/s/ Ian Michael Laing
    
	
16 February 2015, as attorney
    	
)
    	
 
    
	
for NICHOLAS JOHN CROSS:
    	
)
    	
 
    

 

28

 

	
SIGNED by IAN MICHAEL LAING:
    	
)
    	
 
    
	
 
    	
)
    	
/s/ Ian Michael Laing
    

 

29

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 18
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for BENT
    	
)
    	
 
    
	
KARSTEN JAKOBSEN:
    	
)
    	
 
    

 

30

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 18
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for BENTE
    	
)
    	
 
    
	
HELKJAER JAKOBSEN:
    	
)
    	
 
    

 

31

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 13
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for GEORGE
    	
)
    	
 
    
	
EDWARD SILVANUS ROBINSON:
    	
)
    	
 
    

 

32

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 16
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for JOANNE
    	
)
    	
 
    
	
NOBLE:
    	
)
    	
 
    

 

33

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 17
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for WILLIAM
    	
)
    	
 
    
	
THOMAS CHOWN:
    	
)
    	
 
    

 

34

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 13
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for NIGEL
    	
)
    	
 
    
	
STIRLING BLACKWELL:
    	
)
    	
 
    

 

35

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 17
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, duly authorised for and on
    	
)
    	
 
    
	
behalf of Nigel Stirling Blackwell, Nigel
    	
)
    	
 
    
	
Roots and Jane Maitland as trustees for the
    	
)
    	
 
    
	
NIGEL BLACKWELL A&M TRUST:
    	
 
    	
 
    

 

36

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 13
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for
    	
)
    	
 
    
	
CHRISTINA BLACKWELL:
    	
)
    	
 
    

 

37

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 16
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for JANET
    	
)
    	
 
    
	
POINTER:
    	
)
    	
 
    

 

38

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 15
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for 
    	
)
    	
 
    
	
JONATHAN KNOWLES:
    	
)
    	
 
    

 

39

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 16
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for VANNI
    	
)
    	
 
    
	
EMMANUELE TREVES:
    	
)
    	
 
    

 

40

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 20
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, duly authorised for and on
    	
)
    	
 
    
	
behalf of Quester Academic G.P. Limited
    	
)
    	
 
    
	
as general partner of the SECOND ISIS
    	
)
    	
 
    
	
COLLEGE FUND LIMITED
    	
)
    	
 
    
	
PARTNERSHIP:
    	
 
    	
 
    

 

41

 

THE CHANCELLOR MASTERS AND

SCHOLARS OF THE UNIVERSITY

OF OXFORD:

 

 

	
By:
    	
/s/   Christopher Towler
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
Christopher   Towler
    	
 
    
	
 
    	
 
    	
 
    
	
Title:
    	
Director,   OSEM
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
For   and on behalf of
    	
 
    
	
 
    	
THE   CHANCELLOR, MASTERS
    	
 
    
	
 
    	
AND   SCHOLARS OF THE
    	
 
    
	
 
    	
UNIVERSITY   OF OXFORD
    	
 
    

 

42

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 16
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, duly authorised for and on
    	
)
    	
 
    
	
behalf of FINANCIAL CONSULTANTS
    	
)
    	
 
    
	
(JERSEY) LIMITED:
    	
)
    	
 
    

 

43

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 16
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, duly authorised for and on
    	
)
    	
 
    
	
behalf of NUFRAME LIMITED:
    	
)
    	
 
    

 

44

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 13
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, duly authorised for and on
    	
)
    	
 
    
	
behalf of ST CATHERINE’S COLLEGE in
    	
)
    	
 
    
	
the UNIVERSITY OF OXFORD:
    	
 
    	
 
    

 

45

 

	
SIGNED by Ian Michael Laing
    	
))
    	
 
    
	
under a power of attorney dated 17
    	
))
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for PETER
    	
)
    	
 
    
	
LAMMER:
    	
)
    	
 
    

 

46

 

	
SIGNED by Ian Michael Laing
    	
))
    	
 
    
	
under a power of attorney dated 19
    	
))
    	
/s/ Ian Michael Laing
    
	
February 2015, as attorney for HELEN
    	
)
    	
 
    
	
KATRINA TAYTON-MARTIN:
    	
)
    	
 
    

 

47

 

	
SIGNED by Ian Michael Laing
    	
)
    	
 
    
	
under a power of attorney dated 16
    	
)
    	
/s/ Ian Michael Laing
    
	
February 2015, duly authorised for and on
    	
)
    	
 
    
	
behalf of IMMUNOCORE LIMITED:
    	
)
    	
 
    

 

48

 

New Enterprise Associates 14, Limited Partnership

By: NEA Partners 14, Limited Partnership,

its General Partner

 

By: NEA 14 GP, LTD, its General Partner

 

 

	
By:
    	
/s/   Louis Citron
    	
 
    
	
 
    	
 
    
	
Name:   Louis Citron
    	
 
    
	
Title:   Chief Legal Officer
    	
 
    

 

 

By: NEA Ventures 2014, Limited Partnership

 

	
By:
    	
/s/   Louis Citron
    	
 
    
	
 
    	
 
    
	
Name:   Louis Citron
    	
 
    
	
Title:   Vice President
    	
 
    

 

49

 

OrbiMed Private Investments V, L.P.

By: OrbiMed Capital GP V LLC, its

General Partner

 

By: OrbiMed Advisors LLC, its

Managing Member

 

 

	
By:
    	
/s/   Carl Gordon
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
Carl   Gordon
    	
 
    
	
Title:
    	
Member
    	
 
    

 

50

 

SMALLCAP World Fund, Me.

 

 

By: Capital Research and Management Company,

for and on behalf of SMALLCAP World Fund,

Inc., as beneficial holder, and Clipperbay & Co.

(HG22), as nominee for

SMALLCAP World Fund, Inc.

 

 

	
By:
    	
/s/   Walter R. Burkley
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
Walter   R. Burkley
    	
 
    
	
 
    	
 
    	
 
    
	
Title:
    	
Authorized   Signatory
    	
 
    

 

51

 

BEACON BIOVENTURES FUND III

LIMITED PARTNERSHIP

 

By: Beacon Bioventures Advisors Fund III

Limited Partnership,

its General Partner

 

By: Impresa Management LLC,

its General Partner

 

 

	
By:
    	
/s/   Mary Bevelock Pendergast
    	
 
    
	
 
    	
 
    	
 
    
	
Name: Mary Bevelock Pendergast
    	
 
    
	
Title: Vice President
    	
 
    

 

52

 

Ridgeback Capital Management LP

 

	
By:
    	
/s/   Christian Sheldon
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
Christian   Sheldon
    	
 
    
	
 
    	
 
    	
 
    
	
Title:
    	
C.T.O
    	
 
    

 

53

 

Foresite Capital Fund II, L.P.

By: Foresite Capital Management II, LLC

Its: General Partner

 

 

	
By:
    	
/s/   Dennis D. Ryan
    	
 
    
	
 
    	
 
    	
 
    
	
Name: Dennis D. Ryan
    	
 
    
	
Title: CFO
    	
 
    

 

54

 

Novo A/S

 

 

	
By:
    	
/s/   Thomas Dyrberg
    	
 
    
	
 
    	
 
    	
 
    
	
Name: Thomas Dyrberg
    	
 
    
	
Title: Senior Partner
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Novo   A/S

Tuborg   Havnevej 19

DK-2900   Hellerup

Denmark
    	
 
    
				

 

55

 

Salthill Investors (Bermuda) L.P.

 

By: Wellington Management Company LLP

as investment adviser

 

 

	
By:
    	
/s/ Steven M. Hoffman
    	
 
    
	
 
    	
 
    	
 
    
	
Name:   
    	
Steven   M. Hoffman
    	
 
    
	
Title:
    	
Managing   Director and Counsel
    	
 
    

 

 

Salthill Partners, L.P.

 

By: Wellington Management Company LLP

as investment adviser

 

 

	
By:
    	
/s/ Steven M. Hoffman
    	
 
    
	
 
    	
 
    	
 
    
	
Name:   
    	
Steven   M. Hoffman
    	
 
    
	
Title:
    	
Managing   Director and Counsel
    	
 
    

 

56

 

Fourth Avenue Capital Partners LP, by its General Partner,

Fourth Avenue Capital Partners GP LLC

 

 

	
By:
    	
/s/   Tracy Fu
    	
 
    
	
 
    	
 
    
	
Name:   Tracy Fu
    	
 
    
	
Title:   Managing Member
    	
 
    

 

57

 

QVT Fund V LP, by its General Partner,

QVT Associates GP LLC

 

 

	
By:
    	
/s/   Tracy Fu
    	
 
    
	
 
    	
 
    
	
Name:   Tracy Fu
    	
 
    
	
Title:   Managing Member
    	
 
    

 

58

 

Bryan White

 

	
By:
    	
/s/   Bryan White
    	
 
    

 

59

 

Quintessence Fund L.P., its General Partner,

QVT Associates GP LLC

 

 

	
By:
    	
/s/   Tracy Fu
    	
 
    
	
 
    	
 
    
	
Name:   Tracy Fu
    	
 
    
	
Title:   Managing Member
    	
 
    

 

60

 

QVT Fund IV LP, by its General Partner,

QVT Associates GP LLC

 

 

	
By:
    	
/s/   Tracy Fu
    	
 
    
	
 
    	
 
    
	
Name:   Tracy Fu
    	
 
    
	
Title:   Managing Member
    	
 
    

 

61

 

Rock Springs Capital Master Fund LP

 

Rock Springs GP LLC

Its: General Partner

 

 

	
By:
    	
/s/   Kris Jenner
    	
 
    
	
 
    	
 
    
	
Name:   Kris Jenner
    	
 
    
	
Title:   Managing Director (Member)
    	
 
    

 

62

 

venBio Select Fund LLC

 

 

	
By:
    	
/s/   Scott Epstein
    	
 
    
	
 
    	
 
    
	
Name:   Scott Epstein
    	
 
    
	
Title:   CFO & CCO, venBio Select Fund LLC
    	
 
    

 

63

 

Merlin Nexus IV, LP

 

	
By:
    	
/s/   Alberto Bianchinotti
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
Alberto   Bianchinotti
    	
 
    
	
 
    	
 
    	
 
    
	
Title:
    	
CFO
    	
 
    

 

64

 

Sigal Family Investments, LLC

 

 

	
By:
    	
/s/   Elliott Sigal
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
Elliott   Sigal
    	
 
    
	
Title:
    	
Manager
    	
 
    

 

65

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]